Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week high on Thursday . The company traded as high as $110.11 and last traded at $109.7620, with a volume of 261296 shares trading hands. The stock had previously closed at $104.09.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of analyst reports. Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Wedbush raised their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Trading Down 5.1%

The company has a market cap of $5.85 billion, a price-to-earnings ratio of -25.89 and a beta of 1.20. The business has a fifty day moving average price of $92.63 and a two-hundred day moving average price of $78.34.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares of the company’s stock, valued at $2,424,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,779 shares of company stock worth $7,985,235 in the last quarter. 3.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB purchased a new position in Dianthus Therapeutics in the second quarter valued at about $1,491,000. Assenagon Asset Management S.A. purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth about $27,358,000. Seven Fleet Capital Management LP lifted its holdings in shares of Dianthus Therapeutics by 451.6% during the 1st quarter. Seven Fleet Capital Management LP now owns 80,809 shares of the company’s stock valued at $6,781,000 after buying an additional 66,158 shares during the last quarter. DV Trading LLC acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at about $2,228,000. Finally, Glenmede Trust Co. NA lifted its holdings in shares of Dianthus Therapeutics by 96.5% during the 1st quarter. Glenmede Trust Co. NA now owns 12,470 shares of the company’s stock valued at $1,046,000 after buying an additional 6,125 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.